ClinicalTrials.gg
Active, not recruitingNCT05300737SCOREUpdated Nov 5, 2026

Symptomatic Carotid Outcomes Registry

An observational study in Carotid Stenosis, Ischemic Stroke and Transient Ischemic Attack, sponsored by University of Maryland, Baltimore. Active, not recruiting at 18 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Maryland, Baltimore · Observational

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
114
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.

Planned enrollment
16th of 31
114 · median 114
Started
2022
with 3 others
Observational
31 of 84
2 open now
Primary completion
2026-09
later than 4 of 12 live
Registered
76th of 84
by date

Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 16th largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2022, is one of 31 observational ones, reaches primary completion later than 4 of the 12 other live ones, and was the 76th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Carotid Stenosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinical features will be \<5%.

Read the detailed description

This study will only be evaluating clinical care and no interventions will be done specifically for this research.

  • Informed consent from patient or legally authorized representative.
  • Participant survey/questionnaire completion at baseline, 6 and 12 months after enrollment
  • All data collected will be entered into a secure research data registry created for this study.
03

Conditions studied

  • Carotid Stenosis
  • Ischemic Stroke
  • Transient Ischemic Attack
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with 50-99% symptomatic carotid stenosis and low risk clinical or radiologic features

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥40 years plus stroke or ipsilateral to 50-99% ICA stenosis

In addition, patients must have at least one clinical or radiologic marker of reduced stroke risk

Clinical Reduced Stroke RISK:

  1. Retinal ischemia only (amaurosis fugax, branch retinal artery occlusion (BRAO), central retinal artery occlusion (CRAO)
  2. Female sex
  3. Most recent stroke or TIA >1 week ago

Radiologic Reduced Stroke RISK:

  1. Transcranial Doppler (TCD) study demonstrating lack of microembolic signals
  2. Cross-sectional MRI plaque imaging demonstrating absence of intraplaque hemorrhage
  3. For patients with TIA: brain MRI shows no DWI lesion

Exclusion criteria

Exclusion Criteria:

Atrial fibrillation or other high-risk sources of cardiac embolism unless it is device detected AF only or duration \<6 minutes

Alcohol and substance abuse within the prior 24 months

bleeding diathesis ( count \<100K, >14 seconds)

Clear indication for therapeutic anticoagulation (for example, DVT or pulmonary embolism within past 3 months)

\<20%

Known allergy or intolerance to aspirin or clopidogrel

less than 12 months

Moderate/severe dementia (Mini-mental or MOCA score \<22

Modified Rankin score of >4

Nonatherosclerotic cause of carotid stenosis

Most recent symptomatic event >180 days from the time of enrollment

-

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
114 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Symptomatic carotid stenosis with low risk features

    50-99% symptomatic carotid stenosis with low clinical or radiologic risk features (see inclusion criteria) Patients will receive intensive medical therapy, including dual antiplatelet therapy, high potency statins, BP control, and lifestyle modification

    Other: intensive medical therapy

Interventions

  • Otherintensive medical therapy

    Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification

06

What researchers measure

Primary outcomes

  1. Ischemic stroke

    ipsilateral to carotid stenosis, with radiologic confirmation

    Time frame: within 12 months

Secondary outcomes

  1. Myocardial infarction

    ECG will be performed for suspected myocardial infarction and will be diagnosed if appropriate ST changes and confirmation with troponin measurements

    Time frame: within 12 months

07

Study locations

18 sites
08

References and documents

Publications

  • King A, Markus HS. Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis. Stroke. 2009 Dec;40(12):3711-7. doi: 10.1161/STROKEAHA.109.563056. Epub 2009 Oct 22. PubMed 19850894 ↗
  • Chaturvedi S. Treatment of a hot carotid: More fuel is needed to clarify the best treatments. Neurol Clin Pract. 2018 Dec;8(6):466-467. doi: 10.1212/CPJ.0000000000000561. No abstract available. PubMed 30588374 ↗
  • Saba L, Saam T, Jager HR, Yuan C, Hatsukami TS, Saloner D, Wasserman BA, Bonati LH, Wintermark M. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. Lancet Neurol. 2019 Jun;18(6):559-572. doi: 10.1016/S1474-4422(19)30035-3. Epub 2019 Apr 4. PubMed 30954372 ↗
  • Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ; Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004 Mar 20;363(9413):915-24. doi: 10.1016/S0140-6736(04)15785-1. PubMed 15043958 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2026, 49 months.

Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's 49 months is close to that.

Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Mar 29, 2022
StartActual
Aug 1, 2022
Primary completionActual
Sep 25, 2026was Dec 2026
CompletionEst.
May 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Sep 25, 2026 (actual)
Nov 5, 2026
Study completion
Dec 2026→May 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2026→Sep 25, 2026 (now actual)
    Study completion Dec 2026→May 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05300737
Responsible party
Seemant Chaturvedi (Professor of Neurology, University of Maryland, Baltimore) — Principal investigator
First posted
Mar 29, 2022
Start date
Aug 1, 2022
Primary completion
Sep 25, 2026
Completion
May 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Seemant Chaturvedi, MD
principal investigator · School of Medicine, University of Maryland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion